A bitter pill to swallow

Should the NHS buy expensive treatment for a few multiple sclerosis sufferers? Medical history is littered with such difficult decisions, says Nicholas Timmins

Another new and expensive treatment hits the headlines - this time beta-interferon, for the treatment of multiple sclerosis. The drug is not yet licensed but is expected to cost between pounds 7,000 and pounds 10,000 a year. A paper in the British Medical Journal warns that eventually perhaps 45 per cent of Britain's 80,000 MS victims might benefit - a potential bill of pounds 380m annually, or 10 per cent of the National Health Service drugs budget.

A leading article in the same journal thunders that "clearly the NHS is not going to be able to meet the costs of new treatments" - just as the Department of Health insists that the drug will not be rationed.

Is the NHS in crisis over new and high-tech treatments? The answer is no. There is, without doubt, a problem and, for the first generation of patients who might benefit, an acute one. Plainly, not everyone will receive it immediately, not least because there is limited manufacturing capacity and because more research is needed to determine precisely who will benefit and by how much.

The Department of Health estimates that beta-interferon could prove effective for perhaps only one in eight sufferers. None the less, some priorities will have to be set about who gets it, and the issue is raised all the more starkly because beta-interferon is not a cure: it reduces the frequency of relapses.

However, we have been here before; this is not the first time the NHS has felt itself at the mercy of a costly, even unaffordable, technological imperative. That first struck in the Sixties as a string of new and more expensive treatments became available. Health economists calculated in 1967 that 90 per cent of the medicines then available were unknown in 1938 and 50 per cent were unknown five or six years earlier. The NHS survived that apparent crisis and will survive this one.

Projections that such treatments are unaffordable ignores falling real costs over time as products become more widely used. In 1980, Michael Bewick, a transplant surgeon at Dulwich Hospital, south London, virtually bankrupted his health authority single-handed by spending pounds 350,000 - more than pounds 1m in today's money - on an anti-rejection drug. Today, according to Mr Bewick, its real cost has fallen by more than 80 per cent and it is in widespread use around the country.

When Britain's heart transplant programme restarted in the late Seventies and early Eighties, the transplants proved so costly that Patrick Jenkin and Gerry Vaughan, the health ministers, considered stopping the NHS programme as unaffordable. Today the real cost of a heart transplant is down, as it has proved possible to discharge patients earlier. Again, scanners now do more and cost less in real terms than when they were launched, and the same is beginning to apply to the new keyhole surgery equipment and a range of other technological interventions. Medicine is a moving picture, not a static world.

At present, beta-interferon and many of the other new bio-technology products are expensive because they have to be produced in small batch sizes. Some in the industry believe that will always be the case and they will remain permanently expensive. Others hold that someone, somewhere, will find a cheaper way of producing them if the demand is there - a lesson that has applied in the past to a huge range of different technologies, from computers to cars and telecommunications.

This does not mean hard choices do not have to be faced when new treatments first appear. In the late Seventies, in many kidney units the only people to be dialysed were married men, with children, under the age of 55. There were too few machines, the treatment was too expensive, resources had to be concentrated on those who would most benefit and had families to support.

That was a rationing decision far more brutal and harsh than any made in the string of recent announcements by Berkshire, West Yorkshire and one of the Essex health authorities which have been attempting to cut out unproven and ineffective treatments, or by the possible need to restrict the supply of beta-interferon - a treatment which, unlike kidney dialysis, does not save lives.

The dilemma over dialysis reached the media because kidney specialists made a fuss - but it may have created less of a sense of crisis because the process was less transparent and open than the one now being produced by the Government's division of healthcare into purchasers and providers. The process may be more open, but it is no more difficult than in the past.

As more was spent on health, however - and growing nations, seemingly inevitably, spend a higher share of their greater wealth on healthcare - kidney dialysis became much more widely available.

This still leaves hard choices to be made when new treatments first appear. The problem is not unique to the NHS; it is a problem of healthcare everywhere. In the United States, for instance, the most costly and profligate healthcare system in the world, doctors are increasingly being forced by insurers and health maintenance organisations to work to agreed protocols of what can be provided in order to ensure that only effective treatments are provided and costs are contained.

If the beta-interferon treatment does prove to cost pounds 10,000 annually per patient, then, when average earnings are just over pounds 17,000 a year, it is plainly not going to be affordable for everyone instantly, whether on the NHS or not. Private insurance offers no answers here - MS sufferers are anyway not covered for their condition under Bupa-style policies - and beta-interferon would not be, either, because it alleviates a chronic condition but does not provide a cure.

How should such new treatments be handled? The first and crucial thing is to evaluate them properly. The history of modern medicine is littered with "miracle" cures and treatments which proved, on closer examination, to be of far more limited value than the optimists first believed.

For example, for decades, the removal of inflamed tonsils and adenoids was by far the most common operation that ear, nose and throat surgeons performed - more than 190,000 such operations a year as late as the Sixties. But as surgeons and paediatricians came to realise that the condition cleared up spontaneously in many children, the operations dropped - so that fewer than 10,000 are now performed annually.

Equally, the rapid, unevaluated adoption of the monitoring of babies through scalp electrodes, which appeared to offer the prospect of super- safe deliveries, proved to do nothing of the sort when applied indiscriminately. Today, the technique is used much more sparingly and precisely.

Or take an operation for boring out the carotid artery after a stroke to reduce the chances of a second one. The procedure has been performed 20 times more frequently in the US than in Britain, leading to arguments that Britain was rationing it to the point of under-provision. The latest trials, however, according to Bryan Jennett, emeritus professor of neurosurgery at Glasgow University, show it is beneficial only where the artery has become narrow and occluded - the cases on which British surgeons have concentrated. Performed in milder cases, the risks of the operation have been discovered to outweigh the gains.

This does not apply just to surgery. Boots's heart drug, Manoplax, when fully evaluated, was just the latest in a long line of drugs that have failed to live up to their early promise and have had to be withdrawn. By the time beta-interferon is fully evaluated - and its long-term consequences are, inevitably, unknown - it may turn out to be of real value only to a limited group of patients.

How should the decision be made as to who should get it? The department's approach is reasonable. It is to issue guidelines recommending that the drug be prescribed solely by consultant neurologists after a full assessment - ensuring only that those where there appears to be proven benefit receive it, while properly conducted clinical trials establish whether it is of value to other patients.

Is this rationing? Only in the sense that it is rational. Will it deny the treatment to patients who might benefit? Some, initially, inevitably - but that is part of the price of progress, of ensuring that, ultimately, healthcare money is spent on effective treatments, a requirement felt as strongly in privately funded systems as in the NHS.

There is one further point. In the same week that the BMJ was bemoaning beta-interferon's unaffordability, Britain's other leading medical journal, the Lancet, was reporting early but encouraging work on a vaccine for MS. It appears to offer the same benefits - fewer relapses, but no cure - to similar patients to those who look set to gain from beta-interferon. Should it work, its costs may prove a fraction of those of the drug.

Medicine does not stand still. No one can be sure that history will repeat itself and that healthcare will remain affordable, within rising health spending and funded by rising wealth. But it is a not unreasonable bet.

News
Susan Sarandon described David Bowie as
peopleSusan Sarandon reveals more on her David Bowie romance
Sport
Arsenal supporters gather for a recent ‘fan party’ in New Jersey
football
Sport
sportDidier Drogba returns to Chelsea on one-year deal
Arts and Entertainment
The Secret Cinema performance of Back to the Future has been cancelled again
film
PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Life and Style
Balmain's autumn/winter 2014 campaign, shot by Mario Sorrenti and featuring Binx Walton, Cara Delevingne, Jourdan Dunn, Ysaunny Brito, Issa Lish and Kayla Scott
fashionHow Olivier Rousteing is revitalising the house of Balmain
News
people
Arts and Entertainment
Christian Grey cradles Ana in the Fifty Shades of Grey film
filmFifty Shades of Grey trailer provokes moral outrage in US
News
BBC broadcaster and presenter Evan Davis, who will be taking over from Jeremy Paxman on Newsnight
peopleForget Paxman - what will Evan Davis be like on Newsnight?
Life and Style
fashionCustomer complained about the visibly protruding ribs
Voices
The new dawn heralded by George Osborne has yet to rise
voicesJames Moore: As the Tories rub their hands together, the average voter will be asking why they're not getting a piece of the action
Sport
Dejan Lovren celebrates scoring for Southampton although the goal was later credited to Adam Lallana
sport
News
newsComedy club forced to apologise as maggots eating a dead pigeon fall out of air-conditioning
Arts and Entertainment
Jo Brand says she's mellowed a lot
tvJo Brand says shows encourage people to laugh at the vulnerable
Life and Style
People may feel that they're procrastinating by watching TV in the evening
life
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Senior Risk Manager - Banking - London - £650

£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...

Commercial Litigation Associate

Highly Attractive Package: Austen Lloyd: CITY - COMMERCIAL LITIGATION - GLOBAL...

Systems Manager - Dynamics AX

£65000 - £75000 per annum + Benefits: Progressive Recruitment: The client is a...

Service Delivery Manager (Software Development, Testing)

£40000 - £45000 per annum: Ashdown Group: A well-established software house ba...

Day In a Page

Evan Davis: The BBC’s wolf in sheep’s clothing to take over at Newsnight

The BBC’s wolf in sheep’s clothing

What will Evan Davis be like on Newsnight?
Finding the names for America’s shame: What happens to the immigrants crossing the US-Mexico border without documents who never make it past the Arizona desert?

Finding the names for America’s shame

The immigrants crossing the US-Mexico border without documents who never make it past the Arizona desert
Inside a church for Born Again Christians: Speaking to God in a Manchester multiplex

Inside a church for Born Again Christians

As Britain's Anglican church struggles to establish its modern identity, one branch of Christianity is booming
Rihanna, Kim Kardashian and me: How Olivier Rousteing is revitalising the house of Balmain

Olivier Rousteing is revitalising the house of Balmain

Parisian couturier Pierre Balmain made his name dressing the mid-century jet set. Today, Olivier Rousteing – heir to the house Pierre built – is celebrating their 21st-century equivalents. The result? Nothing short of Balmania
Cancer, cardiac arrest, HIV and homelessness - and he's only 39

Incredible survival story of David Tovey

Tovey went from cooking for the Queen to rifling through bins for his supper. His is a startling story of endurance against the odds – and of a social safety net failing at every turn
Backhanders, bribery and abuses of power have soared in China as economy surges

Bribery and abuses of power soar in China

The bribery is fuelled by the surge in China's economy but the rules of corruption are subtle and unspoken, finds Evan Osnos, as he learns the dark arts from a master
Commonwealth Games 2014: Highland terriers stole the show at the opening ceremony

Highland terriers steal the show at opening ceremony

Gillian Orr explores why a dog loved by film stars and presidents is finally having its day
German art world rocked as artists use renowned fat sculpture to distil schnapps

Brewing the fat from artwork angers widow of sculptor

Part of Joseph Beuys' 1982 sculpture 'Fettecke' used to distil schnapps
BBC's The Secret History of Our Streets reveals a fascinating window into Britain's past

BBC takes viewers back down memory lane

The Secret History of Our Streets, which returns with three films looking at Scottish streets, is the inverse of Benefits Street - delivering warmth instead of cynicism
Joe, film review: Nicolas Cage delivers an astonishing performance in low budget drama

Nicolas Cage shines in low-budget drama Joe

Cage plays an ex-con in David Gordon Green's independent drama, which has been adapted from a novel by Larry Brown
How to make your own gourmet ice lollies, granitas, slushy cocktails and frozen yoghurt

Make your own ice lollies and frozen yoghurt

Think outside the cool box for this summer's tempting frozen treats
Ford Fiesta is UK's most popular car of all-time, with sales topping 4.1 million since 1976

Fiesta is UK's most popular car of all-time

Sales have topped 4.1 million since 1976. To celebrate this milestone, four Independent writers recall their Fiestas with pride
10 best reed diffusers

Heaven scent: 10 best reed diffusers

Keep your rooms smelling summery and fresh with one of these subtle but distinctive home fragrances that’ll last you months
Commonwealth Games 2014: Female boxers set to compete for first time

Female boxers set to compete at Commonwealth Games for first time

There’s no favourites and with no headguards anything could happen
Five things we’ve learned so far about Manchester United under Louis van Gaal

Five things we’ve learned so far about United under Van Gaal

It’s impossible to avoid the impression that the Dutch manager is playing to the gallery a little